



#17/CJQ

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rothenberg et al.

SERIAL NUMBER: 09/981,606

EXAMINER: Wilder, Cynthia B.

FILING DATE: October 16, 2001

**ART UNIT: 1656** 

FOR: Mutations Associated with Iron Disorders.

June 17, 2003

Boston, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### PRELIMINARY AMENDMENT

Prior to examination of the above-identified patent application, please amend the application as set forth below and consider the following remarks.

RECEIVED

JUN 2 3 2003

#### In the Claims:

1. (Currently Amended) A method of diagnosing an iron disorder or a genetic susceptibility to developing said disorder in a mammal, comprising determining the presence of a mutation in exon 2 of an HFE nucleic acid in a biological sample from said mammal, wherein said mutation is at position 193 of SEQ ID NO:1 and is not a C → G substitution at nucleotide 187 of SEQ ID NO:1 and wherein the presence of said mutation is indicative of said disorder or a genetic susceptibility to developing said disorder and wherein said determining step is carried out by nucleic acid hybridization on a microchip.

- 3.-24. Cancelled
- 25.-58. Cancelled
- 59. (New) The method of claim 1, wherein said mutation at position 193 of SEQ ID NO:1 is an A → T substitution.



Express Mail Label No.: of Deposit: June 17, 2003



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Rothenberg et al.

SERIAL NUMBER:

09/981,606

EXAMINER:

Wilder, Cythia B.

FILING DATE:

October 16, 2001

ART UNIT:

1656

FOR: Mutations Associated with Iron Disorders

June 17, 2003

Boston, Massachusetts RECEIVED

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

JUN 2 3 2003

### RESPONSE TO RESTRICTION REQUIREMENT

TECH CENTER 1600/2900

In response to the Restriction Requirement mailed on December 17, 2002 (Paper 14), Applicants elect the invention of Group I (claims 1-24), drawn to a method of determining a mutation in exon 2 of an HFE nucleic acid for prosecution in the above-referenced application. Applicants further elect the mutation at nucleotide 193 of SEQ ID NO:1.

Applicants submit herewith a petition for a three month extension of time along with the appropriate fee under 37 CFR 1.17(a)(3). The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 24065-004CON).

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306 Janine M. Susan, Reg. No. 46,119

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542 6000 . Fax: (617) 542-2241